German pharmaceutical company Boehringer Ingelheim announced on Monday that it is launching a new center focused on artificial intelligence and machine learning in London, as part of its efforts to expand the use of advanced technologies in pharmaceutical research and development.
Across the industry, drugmakers are increasingly adopting AI to streamline some of the most time-intensive stages of drug development, including clinical trial recruitment, site selection, and regulatory documentation. However, despite these advancements, industry leaders acknowledge that AI has yet to consistently deliver breakthroughs in the discovery of major new drug molecules.
- Boehringer Ingelheim’s London hub will become its fourth global location, following sites in Austria, Germany, and the United States, focused on advanced computing methods such as algorithms, data analytics, and AI to enhance processes and accelerate discovery
- The center will prioritize the development of targeted medicines aimed at addressing unmet medical needs among patients
- Boehringer Ingelheim plans to invest £150 million (around $200 million) over a 10-year period
- “The UK has a strong legacy in AI, and the government’s continued commitment to advancing data-driven innovation in life sciences and healthcare makes it an ideal location,” said Paola Casarosa, Global Head of the Innovation Unit at Boehringer Ingelheim
- The center will be located near King’s Cross station in the Knowledge Quarter area of London, which hosts several AI-focused companies including OpenAI, Google, and Meta
- United Kingdom has recently positioned itself as an “AI superpower” and a hub for cutting-edge research and innovation
- Roche has also expanded its AI computing capabilities, adding more than 2,100 chips from Nvidia
($1 = 0.7407 pounds)
